Hope Rugo, MD

Articles

Dr Rugo on the FDA Approval of Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

October 11th 2024

Hope S. Rugo, MD, discusses the FDA approval of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutated, HR+/HER2– metastatic breast cancer.

Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

October 2nd 2024

Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.

Expert Insights: Investigational ADCs Safety Profiles

September 25th 2024

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

Future Perspectives on ADCs in Breast Cancer

September 24th 2024

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

September 18th 2024

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

September 18th 2024

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

Clinical Management Considerations: Pneumonitis associated with T-DXd

September 11th 2024

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.

Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

September 11th 2024

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

Expert Insights: SG Adverse Events Management including Alopecia & Nausea

September 4th 2024

Panelists discuss how to manage side effects of sacituzumab govitecan (SG), including counseling on alopecia, proactive management strategies, routine antiemetic premedications, and adjustments for chemotherapy-induced nausea and vomiting, as well as recommended breakthrough antinausea medications for home use.

Navigating SG-related Diarrhea

September 4th 2024

Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.

Expert Perspectives on the Management of SG-Related Neutropenia

August 28th 2024

This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.

Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

August 28th 2024

This discussion explores the occurrence and risk factors of neutropenia associated with SG treatment, comparing clinical practice experiences with trial data.

ADCs in Breast Cancer: Mechanism of Action, and Components

August 21st 2024

Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.

Overview of Current ADCs in Breast Cancer

August 21st 2024

Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).

Dr Rugo on Challenges Faced as a Woman in Oncology

March 11th 2024

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

Dr Rugo on the Evolution of ADCs in HR+/HER2+ and HER2-Low Breast Cancer

March 9th 2024

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.

Dr. Rugo on HER2 Differentiation in Metastatic Breast Cancer

November 9th 2022

Hope Rugo, MD, discusses the challenges of differentiating between HER2-low and HER2-negative metastatic breast cancer and prognostic differences in HER2+ and HER2-low metastatic breast cancer.

Dr. Rugo on the Benefit of Margetuximab Plus Chemotherapy in HER2+ Metastatic Breast Cancer

March 6th 2021

Hope S. Rugo, MD, discusses the benefit of margetuximab-cmkb in patients with HER2-positive breast cancer who have received prior HER2-targeted therapies.

Dr. Rugo on the Significance of Becoming a Giant in Cancer Care

December 3rd 2020

Hope S. Rugo, MD, discusses the significance of becoming a Giant of Cancer Care®.

Dr. Rugo on the Optimal Setting for Biosimilar Evaluation

November 20th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the optimal setting for biosimilar evaluation.